538184 Synoviolin Inhibitor, LS-102 - Calbiochem

538184
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₂₄H₃₆N₈O

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      5.38184.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable triaminotriazine that selectively inhibits the autoubiquitnation of the E3 ubiquitin ligase synoviolin (SYVN1, IC50 = 35 µM), without affecting other E3 ubiquitin ligases. Abolished the SYVN-mediated negative regulation of PGC-1β via reduced ubiquitination. Shown to induce the expression of PGC-1β in wild type mouse embryonic fibroblasts (MEF), but does not affect PGC-1β expression in SYVN knockout MEFs. Increases mitochondrial biogenesis in C57BL/6J mice. Also increases the energy expenditure and causes a significant reduction in body weight and blood glucose levels in db/db mice (50 mg/kg, i.p daily) without influencing their food intake. Suppresses the proliferation of rheumatoid synovial cells (IC50 = 5.4 µM) and reduces the severity of rheumatoid arthritis in a mouse model (4 mg/kg).

          Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
          Catalogue Number538184
          Brand Family Calbiochem®
          Synonyms(S)-N²-(benzo[d]oxazol-6-yl)-N⁴-(1-cyclohexylethyl)-N⁶-ethyl-N⁶-(2-(ethylamino)ethyl)-1,3,5-triazine-2,4,6-triamine, E3 Ligase SYVN Inhibitor, LS-102, LS102
          References
          ReferencesYagishita, N., et al. 2012. Int. J. Mol. Med. 30, 1281.
          Fujita, F., et al. 2015. EMBO J. 34, 12192.
          Product Information
          FormPurple solid
          Hill FormulaC₂₄H₃₆N₈O
          Chemical formulaC₂₄H₃₆N₈O
          ReversibleY
          Applications
          Biological Information
          Primary TargetSynoviolin
          Primary Target IC<sub>50</sub>35 µ
          Purity≥97% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Synoviolin Inhibitor, LS-102 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Yagishita, N., et al. 2012. Int. J. Mol. Med. 30, 1281.
          Fujita, F., et al. 2015. EMBO J. 34, 12192.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision16-March-2017 JSW
          Synonyms(S)-N²-(benzo[d]oxazol-6-yl)-N⁴-(1-cyclohexylethyl)-N⁶-ethyl-N⁶-(2-(ethylamino)ethyl)-1,3,5-triazine-2,4,6-triamine, E3 Ligase SYVN Inhibitor, LS-102, LS102
          DescriptionA cell-permeable triaminotriazine that selectively inhibits the autoubiquitnation of the E3 ubiquitin ligase synoviolin (SYVN1, IC50 = 35 µM), without affecting other E3 ubiquitin ligases. Abolished the SYVN-mediated negative regulation of PGC-1β via reduced ubiquitination. Shown to induce the expression of PGC-1β in wild type mouse embryonic fibroblasts (MEF), but does not affect PGC-1β expression in SYVN knockout MEFs. Increases mitochondrial biogenesis in C57BL/6J mice. Also increases the energy expenditure and causes a significant reduction in body weight and blood glucose levels in db/db mice (50 mg/kg, i.p daily) without influencing their food intake. Suppresses the proliferation of rheumatoid synovial cells (IC50 = 5.4 µM) and reduces the severity of rheumatoid arthritis in a mouse model (4 mg/kg).
          FormPurple solid
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₂₄H₃₆N₈O
          Purity≥97% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesYagishita, N., et al. 2012. Int. J. Mol. Med. 30, 1281.
          Fujita, F., et al. 2015. EMBO J. 34, 12192.